DSIP (Delta Sleep-Inducing Peptide)5mg

DSIP (Delta Sleep-Inducing Peptide) 5mg is a synthetic peptide known for its potential role in promoting deep, restorative sleep and regulating sleep patterns. Originally discovered in the hypothalamus, DSIP has been extensively studied for its influence on neuroendocrine functions, stress response, and circadian rhythms.

This peptide is often used in research settings to explore its ability to support:

• Improved Sleep Quality – DSIP may help reduce sleep latency and increase the duration of slow-wave (deep) sleep without sedation.
• Stress Reduction – It has shown potential in regulating stress hormones such as cortisol, which can positively impact mood and resilience.
• Pain Modulation – DSIP may play a role in analgesia by modulating sensory thresholds and interacting with opioid pathways.
• Hormonal Regulation – DSIP has been observed to influence LH, GH, and ACTH levels in clinical research.
• Antioxidant and Neuroprotective Effects – Potentially helps protect brain cells and reduce oxidative stress.

Each vial contains 5mg of pure DSIP in lyophilized powder form, designed for reconstitution and use in laboratory research only. It is not intended for human consumption or therapeutic use outside of approved clinical trials.

Key Information:

• Purity: ≥ 98% (HPLC)
• Form: Lyophilized Powder
• Storage: Store at -20°C; protect from light and moisture
• Reconstitution: Sterile bacteriostatic water recommended

Disclaimer:
DSIP (Delta Sleep-Inducing Peptide) 5mg is sold strictly for research purposes only. Not for human or veterinary use. Purchasers must be qualified professionals.

DSIP Peptide 

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide that plays a role in regulating sleep, especially deep or slow-wave sleep. Originally discovered in the brains of rabbits in the 1970s, DSIP has since been studied for its potential effects on sleep regulation, stress reduction, hormone modulation, and neuroprotection.

Though its full mechanism of action is still being researched, DSIP is believed to interact with various neurotransmitter systems, including serotonin and GABA. It may help reduce sleep onset time, improve overall sleep quality, and promote more restful, restorative sleep without causing sedation or dependency.

In research settings, DSIP has also shown promise for:

• Supporting the body’s natural circadian rhythms

• Modulating stress-related hormones such as cortisol

• Enhancing resistance to oxidative stress in neural tissue

• Potential analgesic (pain-relieving) effects

DSIP is typically available in lyophilized peptide form and used under controlled research conditions. It is not approved for human use outside of clinical research.

Delta Sleep Inducing Peptide 

Delta Sleep-Inducing Peptide, commonly known as DSIP, is a neuropeptide that has been studied for its role in promoting deep, restorative sleep. First isolated in the 1970s, DSIP is naturally present in the hypothalamus and has been associated with sleep regulation, especially in enhancing slow-wave (delta) sleep cycles.

Unlike sedative medications, DSIP doesn’t cause drowsiness but may help normalize disrupted sleep patterns by influencing the body’s natural sleep-wake rhythms. It is also thought to affect hormone secretion, including growth hormone and cortisol, and may have a role in reducing stress, enhancing mood, and protecting the brain from oxidative damage.

Researchers are investigating DSIP for its potential benefits in:

• Improving sleep quality and duration
• Reducing stress and anxiety levels
• Regulating hormonal balance
• Supporting pain management and neuroprotection

While promising in early studies, DSIP is still classified as a research peptide and is not approved for medical or therapeutic use in humans.

DSIP and sleep

The innate controlling mechanisms of sleep have fascinated scientists for generations and many different endogenous compounds have been proposed as controllers of sleep over the years. These include cholecystokinin, prostaglandin I2 and various unknown substances labelled ‘sleep-promoting substances’. Indeed, the majority of humoral mediators seem to have some relation to sleep by, for example, affecting circadian rhythms or arousal states. In some cases, however, it is not clear if the humoral mediator is driving the sleep pattern or responding to the sleep pattern.

Since the discovery of DSIP a number of studies have been undertaken to test the hypothesis that DSIP may be the principal endogenous sleep factor. It is reported to increase the ‘pressure to sleep’ in human subjects who have been injected with small doses and this, together with its ability to induce delta-wave sleep, led to its consideration as a treatment for insomnia. A number of studies have examined this use with varied success.

DSIP has been described as a sleep-promoting substance rather than a sedative. There is a modulating effect on sleep and wake functions with a greater activity in circumstances where sleep is disturbed. There are minimal effects in healthy subjects who are not suffering from sleep disturbance. DSIP is not a night sedation drug which needs to be given just before retiring. A dose of DSIP given during the course of the day will promote improved sleep on the next night and for several nights thereafter. Despite these clear short-term benefits, however, doubt has been cast on whether or not DSIP treatment will prove to be of major benefit in long-term management of insomnia.

Studies have been undertaken in patients suffering from the sleep apnoea syndrome and from narcolepsy. Unfortunately, no difference in DSIP concentrations has been found between those patients and normal patients. DSIP may, paradoxically, be of use in the treatment of narcolepsy and it is possible that it exerts its effect by restoring circadian rhythms. When single and multiple injections of DSIP were given in a controlled double-blind study, disturbed sleep was normalized and better performance and increased alertness was seen during awake cycles together with improved stress tolerance and coping behaviour.

Non-sleep effects

DSIP has been shown to have an anticonvulsant action in the rat. The threshold to NMDA- and picrotoxin-induced convulsions is increased by DSIP. This anticonvulsant effect may undergo a diurnal variation with greater antiepileptic activity seen at night. DSIP is not unique in possessing a diurnal variation in anticonvulsant activity as melatonin, b-endorphin and dexamphetamine all reduce seizure threshold during the day and it is possible that DSIP simply represents one of the endogenous controls of brain excitability. DSIP has an antinociceptive action in mice, an effect which is blocked by naloxone.

A neuroprotective effect has been demonstrated in rats subjected to bilateral carotid ligation. A reduced mortality was observed together with a reduction in postischaemia function. DSIP also reduced brain swelling in a model of toxic cerebral oedema in the rat.

DSIP attenuates emotional and psychological responses to stress and also reduces the central amine responses to stress in rats. The action of corticotrophin releasing factor on the pituitary gland in the rat is attenuated with a consequential inhibition of pituitary adrenocorticotrophic hormone (ACTH) secretion. The situation is less clear in man as although one study confirmed this finding  another reported no inhibitory effect on the adrenocortical axis to both physiological and stressor stimuli. DSIP had no effect on growth hormone or prolactin concentrations when administered to human volunteers In one study, infusions of 3 or 4 mg (an enormous dose) had no effect on ACTH levels or on cortisol secretion although in another study DSIP 25 nmol kg^–1 significantly decreased ACTH concentrations .

DSIP concentrations change during certain psychiatric disorders. Patients suffering from schizophrenia and depression have lower plasma and cerebrospinal fluid concentrations of DSIP than comparable normal volunteers. Concentrations were also inversely correlated with sleep disturbance in those patients.

As might be expected of any substance which is naturally occurring, side-effects are uncommon. Normally, concentrations would be very low and therefore the injection of large, probably non-physiological doses might be expected to at least produce some unwanted effect. No significant side-effects have so far been reported with DSIP. In some human studies, transient headache, nausea and vertigo have been reported. DSIP actually appears to be incredibly safe as its LD₅₀ has never been determined because it has never so far proved possible to kill an animal whatever the dose of DSIP administered.

Clinical uses

Clinical uses for DSIP already exist. The agent has been used for the treatment of alcohol and opioid withdrawal with some success. Clinical symptoms and signs disappear after injection of DSIP although some patients have reported occasional headaches.

DSIP possesses a number of other apparently unrelated properties. In hypertensive rats, 200 μg kg⁻¹ day⁻¹of DSIP for 10 days had an antihypertensive effect. DSIP has also been reported to possess antimetastatic activity. It may also reduce amphetamine-induced hyperthermia and may be beneficial in some chronic pain conditions.

An interesting study reported in 1986 injected DSIP and several analogues of the peptide directly into the cerebral ventricle of rats. DSIP did not increase sleep and this was thought to be due to its very rapid metabolism. However, two of the analogues did induce sleep but one produced arousal. It would appear therefore that there might be the potential for not only sleep but sleep reversal within the analogues of DSIP.

The molecular sites for the action of anaesthetic agents are being identified. Volatile agents appear to act on specific sites of the GABA-A and glycine receptors, whereas ketamine and xenon act on the NMDA receptors. These sites are reproducible and clearly defined, but what is their natural purpose, as neither volatile anaesthetic agents nor xenon are usually found in physiological systems? It is possible, but has yet to be demonstrated, that DSIP and other neuroactive peptides selectively bind to these regions of GABA-A, glycine and/or NMDA receptors.

Is DSIP of relevance to the anaesthesiologist?

Anaesthesia is physiologically distinct from natural sleep and anaesthetic agents appear to work on receptor mechanisms normally dedicated to the control of brain metabolism. Conventional sleep staging does not indicate the depth of anaesthesia; rapid-eye movements (REM) and other characteristics of natural sleep are not seen during anaesthesia. It is possible, however, that anaesthesia is mimicking a natural phenomenon such as hibernation by copying the action of natural neuroactive peptides such as DSIP.

What is the significance of DSIP to anaesthesia? Could DSIP be the body’s natural anaesthetic? Is activation of the DSIP receptors related to the state of anaesthesia? These questions must remain speculative for the present. Whether or not DSIP is the body’s natural anaesthetic, or a substance closely involved in this process, it may not prove to be possible to administer it in a way which could be regarded as anaesthesia. Could it therefore be used as the body’s natural sedative? No studies have been performed to investigate this possible use although it would theoretically seem to have potential.

Key Benefits of DSIP:

✔ Improves Sleep Quality – Helps induce delta-wave sleep, the deepest and most restorative phase of sleep.
✔ Reduces Stress & Anxiety – May lower cortisol levels and promote relaxation.
✔ Enhances Recovery – Supports muscle recovery, immune function, and overall physical well-being.
✔ Regulates Hormonal Function – May help modulate the release of hormones like cortisol, LH, and growth hormone.
✔ Supports Mental Clarity – By improving sleep patterns, DSIP can help enhance cognitive function and mood.

How DSIP Works

DSIP interacts with the central nervous system to influence sleep regulation and stress response. It is believed to promote sleep by affecting the brain’s neurotransmitters, reducing the effects of stress-related hormones, and increasing natural sleep-promoting mechanisms. Unlike traditional sleep aids, DSIP does not cause sedation but instead encourages natural sleep onset and maintenance.

Who Can Benefit from DSIP?

• Individuals struggling with poor sleep or insomnia

• Athletes and fitness enthusiasts looking to enhance recovery

• People dealing with high stress or irregular sleep cycles

• Those seeking a natural way to improve deep sleep quality

Note: DSIP is primarily used in research settings and is not approved for medical use. Always consult a healthcare professional before use.

FAQs – DSIP (Delta Sleep-Inducing Peptide) 5mg

1. What is DSIP (Delta Sleep-Inducing Peptide)?
DSIP is a neuropeptide originally found in the hypothalamus and studied for its potential role in promoting deep, restful sleep, modulating stress responses, and regulating hormone levels.

2. What is DSIP 5mg used for?
In research settings, DSIP 5mg is used to study its effects on improving sleep quality, reducing cortisol levels, enhancing mood, and supporting neuroprotection. It is not approved for medical or therapeutic use.

3. How does DSIP affect sleep?
DSIP may help regulate sleep patterns by increasing slow-wave (deep) sleep without acting as a sedative. It works by influencing neurochemical pathways related to circadian rhythm and relaxation.

4. Is DSIP the same as a sleeping pill?
No. Unlike traditional sedatives or sleeping pills, DSIP does not induce sleep directly. It may help the body achieve more natural and restorative sleep through hormonal and neurochemical regulation.

5. How is DSIP 5mg typically administered?
In research, DSIP is usually reconstituted with sterile water and administered via subcutaneous injection. However, all usage should be strictly for laboratory and investigational purposes only.

6. Are there any known side effects of DSIP?
There is limited human data. Some users in research contexts have reported fatigue, vivid dreams, or mood shifts. DSIP has not been formally approved for clinical use, so long-term effects are unknown.

7. Can DSIP be used daily?
Frequency of use varies by research protocol. Long-term or frequent use should only be explored under strict research oversight. It is not intended for personal use or self-medication.

8. Is DSIP legal to purchase?
DSIP is legal for purchase in many countries for research purposes only. It is not a controlled substance but should not be sold or used as a dietary supplement or drug.

9. How should DSIP 5mg be stored?
Unreconstituted DSIP should be kept in a cool, dry place—preferably refrigerated or frozen. Once mixed, it should be used promptly or stored according to peptide stability guidelines.

10. Who should not use DSIP?
DSIP should not be used by anyone outside of controlled research environments. It is not safe or legal for use in humans or animals without proper regulatory approval.